Seeking Alpha

Mylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from...

Mylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from the FDA for its Pioglitazone Tablets, the generic versions of Takeda Pharmaceutical's Actos Tablets and Actoplus Met Tablets. The pills are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|